Firstly, I don't think comparing Esperion at 2 plus years to RVX at 2 plus years is useful as Esperion is now entering phase 3 while RVX at 2 plus years was still pre-clinical. That being said, the point of this comparision was not about market cap per se but more as a comparision of management efficiencies as they affect market cap. Although I would never expect them to have exactly the same market cap they are two biotechs going into phase 3 in a somewhat similar area of the cardiovascular space. One company valued much higher than the other, one company with a truly experienced CEO with a real track record who apparently knows among other things the importance of proper guidance and who runs his ship accordingly and the other with a CEO who can't seem to get out of his own way.

Irrespective of the fact that Esperion has achieved phase 3, although not exactly from square one, much more quickly than RVX, the comparision was to illustrate that, in a nutshell, taking care of business often results in good share price performance.

I remember when RVX spiked to almost $30. Pfizer had just given up on Torcetrapib and the rumour around Calgary was that DM had a big offer on his desk but was holding out for more. Luckily for me I felt a market cap of almost $1 billion was ridiculous for a pre-clinical cardio company.